Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Total Debt: 2020-2022

  • Mereo BioPharma Group's Total Debt fell 97.49% to $486,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $486,000, marking a year-over-year decrease of 97.49%. This contributed to the annual value of $486,000 for FY2022, which is 97.49% down from last year.
  • Mereo BioPharma Group's Total Debt amounted to $486,000 in Q4 2022, which was up 2,319.29% from $20,089 recorded in Q2 2022.
  • Mereo BioPharma Group's 5-year Total Debt high stood at $26.8 million for Q2 2021, and its period low was $20,089 during Q2 2022.
  • Over the past 3 years, Mereo BioPharma Group's median Total Debt value was $18.7 million (recorded in 2020), while the average stood at $14.4 million.
  • Its Total Debt has fluctuated over the past 5 years, first spiked by 48.91% in 2021, then crashed by 99.93% in 2022.
  • Mereo BioPharma Group's Total Debt (Quarterly) stood at $21.9 million in 2020, then decreased by 11.33% to $19.4 million in 2021, then plummeted by 97.49% to $486,000 in 2022.
  • Its last three reported values are $486,000 in Q4 2022, $20,089 for Q2 2022, and $19.4 million during Q4 2021.